Cargando…
晚期EGFR突变型非小细胞肺癌患者接受吉非替尼或厄洛替尼治疗的成本效益分析
BACKGROUND AND OBJECTIVE: Targeted therapy in non-small cell lung cancer (NSCLC) had become a research hotspot.Both of gefitinib and erlotinib had already been recommended as first line treatment in epidermal growth factor receptor (EGFR) mutant advanced NSCLC patients.The study aimed to compare the...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
中国肺癌杂志编辑部
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000588/ https://www.ncbi.nlm.nih.gov/pubmed/23601301 http://dx.doi.org/10.3779/j.issn.1009-3419.2013.04.06 |
Ejemplares similares
-
厄洛替尼治疗晚期非小细胞肺癌分类及回归树分析
Publicado: (2011) -
厄洛替尼100 mg/天治疗化疗后进展的晚期肺腺癌的临床研究
Publicado: (2011) -
吉非替尼治疗32例肺腺癌脑转移的临床经验
Publicado: (2015) -
80例晚期NSCLC吉非替尼治疗长于6个月患者的预后因素分析
Publicado: (2010) -
吉非替尼联合心包灌注治疗晚期非小细胞肺癌的疗效观察
Publicado: (2018)